Clinical Trial

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-19; most recent amendment 2026-05-14.
Trial Details
NCT Number NCT06980623
Lead Sponsor Brigham and Women's Hospital
Conditions Type 2 Diabetes, Heart Failure
Enrollment 26,000 participants
Start Date 2025-01-01
Primary Completion 2025-11-30 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15